Intriguingly, both “writers” inhibition (METTL3 or METTL14) and “erasers” inhibition (FTO or ALKBH5) are proved to enhance the efficacy of anti-PD-1 blockade even in the same cancer (melanoma). This evidence concerns the gene METTL3 and cancer.